Progressive multifocal leukoencephalopathy: Current treatment options and future perspectives

Therapeutic Advances in Neurological Disorders

Volumn 8, Issue 6, 2015, Pages 255-273

  Pavlovic, Dejan ^a   Patera, Andriani C ^a   Nyberg, Fredrik ^b   Gerber, Marianne ^c   Liu, Maggie ^d  

^a MEDIMMUNE   (United States)

^b ASTRAZENECA R AND D   (Sweden)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d Progressive Multifocal Leukeoncephalopathy Consortium Secretariat   (United States)

Author keywords

anti viral; HIV; IL 7; immunosuppression; interferon; IRIS; JCV; natalizumab; PML; PML IRIS; prophylaxis; treatment; vaccine

Indexed keywords

3 AMINOBENZAMIDE; AG 122; ALPHA INTERFERON; ANTIVIRUS AGENT; BREFELDIN A; BRINCIDOFOVIR; CHLORPROMAZINE; CIDOFOVIR; CITALOPRAM; CYT 107; CYTARABINE; GANCICLOVIR; GLUCOCORTICOID; IMATINIB; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2; INTERLEUKIN 7; LEFLUNOMIDE; MARAVIROC; MEFLOQUINE; MIRTAZAPINE; NATALIZUMAB; RETRO 2CYCL; RISPERIDONE; SMALL INTERFERING RNA; TOPOTECAN; UNCLASSIFIED DRUG; ZIDOVUDINE; ZIPRASIDONE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CENTRAL NERVOUS SYSTEM INFECTION; CHRONIC DISEASE; CYTOMEGALOVIRUS RETINITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNE RESPONSE; IMMUNOTHERAPY; INCIDENCE; JC VIRUS; MEDICAL HISTORY; MULTIPLE SCLEROSIS; NONHUMAN; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROPHYLAXIS; RARE DISEASE; REVIEW; SURVIVAL; VIRUS INFECTION;

EID: 84945556497     PISSN: 17562856     EISSN: 17562864     Source Type: Journal    
DOI: 10.1177/1756285615602832     Document Type: Review

References (106)

1. Alstadhaug K. Croughs T. Henriksen S. Leboeuf C. Sereti I. Hirsch H. et al. (2014) Treatment of progressive multifocal leukoencephalopathy with interleukin 7. JAMA Neurol 71: 1030–1035.
2. Antoniol C. Jilek S. Schluep M. Mercier N. Canales M. Le Goff G. et al. (2012) Impairment of JCV-specific T-cell response by corticotherapy: effect on PML-IRIS management? Neurology 79 (23): 2258–2264.
3. Astrom K. Mancall E. Richardson E. Jr (1958) Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease. Brain 81 (1): 93–111.
4. Atwood W. (2001) A combination of low-dose chlorpromazine and neutralizing antibodies inhibits the spread of JC virus (JCV) in a tissue culture model: implications for prophylactic and therapeutic treatment of progressive multifocal leukencephalopathy. J Neurovirol 7: 307–310.
5. Agostini H. Ryschkewitsch C. Singer E. Stoner G. (1997) JC virus regulatory region rearrangements and genotypes in progressive multifocal leukoencephalopathy: two independent aspects of virus variation. J Gen Virol 78: 659–664.
6. Balduzzi A. Lucchini G. Hirsch H. Basso S. Cioni M. Rovelli A. et al. (2011) Polyomavirus JC-targeted T-cell therapy for progressive multiple eukoencephalopathy in a hematopoietic cell transplantation recipient. Bone Marrow Transplant 46: 987–992.
7. Bayliss J. Karasoulos T. McLean C. (2013) Immunosuppression increases JC polyomavirus large T antigen DNA load in the brains of patients without progressive multifocal leukoencephalopathy. J Infect Dis 207: 133–136.
8. Berger J. Pall L. Lanska D. Whiteman M. (1998) Progressive multifocal leukoencephalopathy in patients with HIV infection. J Neurovirol 4: 59–68.
9. Berger J. Pall L. McArthur J. Hall C. Cimoch P. Evans B. et al. (1992) A pilot study of recombinant alpha 2a interferon in the treatment of AIDS-related progressive multifocal leukoencephalopathy. Neurology 42(Suppl. 3): 257.
10. Bernhoff E. Gutteberg T. Sandvik K. Hirsch H. Rinaldo C. (2008) Cidofovir inhibits polyomavirus BK replication in human renal tubular cells downstream of viral early gene expression.Am J Transplant 8: 1413–1422.
11. Bernhoff E. Tylden G. Kjerpeseth L. Gutteberg T. Hirsch H. Rinaldo C. (2010) Leflunomide inhibition of BK virus replication in renal tubular epithelial cells. J Virol 84: 2150–2156.
12. Biogen-Idec (2011) Natalizumab PML risk update, July 2011. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Presentation/2011/07/WC500109645.pdf (accessed August 2015)
13. Biogen-Idec (2014) Natalizumab PML risk update, February 2014. Available at: http://multiple-sclerosis-research.blogspot.com/2014/03/natalizumab-pml-risk-update-february.html (accessed August 2015).
14. Bloomgren G. Richman S. Hotermans C. Subramanyam M. Goelz S. Natarajan A. et al. (2012) Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 366: 1870–1880.
15. Bofill-Mas S. Formiga-Cruz M. Clemente-Casares P. Calafell F. Girones R. (2001) Potential transmission of human polyomaviruses through the gastrointestinal tract after exposure to virions or viral DNA. J. Virol 75: 10290–10299.
16. Boland C. (2012) JC virus vaccine. Patent EP 2465532 A1.
17. Brew B. Davies N. Cinque P. Clifford D. Nath A. (2010) Progressive multifocal leukoencephalopathy and other forms of JC virus disease. Nat Rev Neurol 6: 667–679.
18. Brickelmaier M. Lugovskoy A. Kartikeyan R. Reviriego-Mendoza M.M. Allaire N. Simon K. et al. (2009) Identification and characterization of mefloquine efficacy against JC virus in vitro. Antimicrob Agents Chemother 53: 1840–1849
19. Brosgart C. Roberts T. Safrin S. et al. (1997) Cidofovir therapy for PML in two AIDS patients. [Abstract I-5] 37th ICAAC.
20. Buckanovich R.J. Liu G. Stricker C. Luger S.M. Stadtmauer E.A. Shuster S.J. et al. (2002) Nonmyeloablative allogeneic stem cell transplantation for refractory Hodgkin's lymphoma complicated by interleukin-2 responsive progressive multifocal leukoencephalopathy. Ann Hematol 81: 410–3.
21. Carson K.R. Newsome S.D. Kim E.J. Wagner-Johnston N.D. von Geldern G. Moskowitz C.H. et al. (2014) Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project. Cancer 120: 2464–71.
22. Cettomai D. McArthur J.C. (2009) Mirtazapine use in human immunodeficiency virus–infected patients with progressive multifocal leukoencephalopathy. Arch Neurol 66: 255–258
23. Chapagain M.L. Sumibcay L. Gurjav U. Kaufusi P. Kast R.E. Nerurkar V.R. (2008) Serotonin receptor 2A blocker (risperidone) has no effect on human polyomavirus JC infection of primary human fetal glial cells. J Neurovirol 14:448–54
24. Cinque P. Koralnik I.J. Gerevini S. Miro J.M. Price R.W. (2009) Progressive multifocal leukoencephalopathy in HIV-1 infection. Lancet Infect Dis 9: 625–636
25. Cinque P. Pierotti C. Viganò M.G. Bestetti A. Fausti C. Bertelli D. et al. (2001) The good and evil of HAART in HIV-related progressive multifocal leukoencephalopathy. J. NeuroVirol 7: 358–363.
26. Clifford D. (2014) Progressive multifocal leukoencephalopathy therapy. J Neurovirol. [epub ahead of print]
27. Clifford D. Ances B. Costello C. Rosen-Schmidt S. Andersson M. Parks D. et al. (2011) Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neuro 68: 1156–1164.
28. Clifford D. Nath A. Cinque P. Brew B. Zivadinov R. Gorelik L. et al. (2013) A study of mefloquine treatment for progressive multifocal leukoencephalopathy: Results and exploration of predictors of PML outcomes. J Neurovirol 19: 351–358.
29. ClinicSpeak (2015) Natalizumab PML update - Q 4 2014, January 2015. Available at: http://multiple-sclerosis-research.blogspot.com/2015/01/clinicspeak-natalizumab-pml-update-q4.html (accessed August 2015).
30. Dahlhaus S. Hoepner R. Chan A. Kleiter I. Adams O. Lukas C. et al. (2013) Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients. J Neurol Neurosurg Psychiatry 84: 1068–1074.
31. D'Arminio Monforte A. Cinque P. Mocroft A. Goebel F. Antunes F. Katlama C. et al. (2004) Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol 55: 320–328.
32. de Luca A. Ammassari A. Pezzotti P. Cinque P. Gasnault J. Berenguer J. Di Giambenedetto S. et al. (2008) Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis. AIDS 22:1759–1767.
33. Demir E. Liebert U. Söylemezoglu F. Yalaz K. Köse G. Anlar B. (2005) Childhood case of progressive multifocal leukoencephalopathy with improved clinical outcome. J Child Neurol 20: 241–244.
34. De-Simone F. Sariyer R. Lopez Otalora Y. Yarandi S. Michael Craigie M. Gordon J. et al. (2015) IFN-gamma inhibits JC virus replication in glial cells by suppressing T-antigen expression. PloS ONE. DOI: 10.1371/journal.pone.0129694.
35. Elphick G. Querbes W. Jordan J. Gee G. Eash S. Manley K. et al. (2004) The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science 306: 1380–1383.
36. Engsig F. Hansen A. Omland L. Kronborg G. Gerstoft J. Laursen A. et al. (2009) Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: A nationwide cohort study. J Infect Dis 199: 77–83.
37. Epker J. van Biezen P. van Daele P. van Gelder T. Vossen A. van Saase J. (2009) Progressive multifocal leukoencephalopathy, a review and an extended report of five patients with different immune compromised states. Eur J Intern Med 20: 261–267.
38. Epperla N. Yale S. (2013) Drugs smarter than bugs: Mirtazapine and mefloquine for non-AIDS-related progressive multifocal leukoencephalopathy. J Hospital Med 8(Suppl. 1): 954.
39. Friedman R. (2011) Malaria drug fails to fulfill promise in PML. Neurol. Today 11 (8): 8.
40. Gaffena S. Liub K. (2004) Overview of interleukin-2 function, production and clinical applications. Cytokine 28: 109–123.
41. Gasnault J. de Goer d.e. Havre M. Michot J. Hendel-Chavez H. Seta V. Mazet A. et al. (2014) Efficacy of recombinant human interleukin 7 in a patient with severe lymphopenia-related progressive multifocal leukoencephalopathy. Open Forum Infect Dis 1: 1–3.
42. Gasnault J. Costagliola D. Hendel-Chavez H. Dulioust A. Pakianather S. Mazet A. et al. (2011) Improved survival of HIV-1-infected patients with progressive multifocal leukoencephalopathy receiving early 5-drug combination antiretroviral therapy. PloS ONE 6: e20967.
43. Giacomini P. Rozenberg A. Metz I. Araujo D. Arbour N. Bar-Or A. (2014) Maraviroc and JC virus–associated immune reconstitution inflammatory syndrome. N Engl J Med 370: 486.
44. Grimm J. Martin R. Combaluzier B. (2014) Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases. Patent WO2014102399A1.
45. Gosert R. Hanssen R. Wernli M. Major E. Hirsch H. (2011) CMX 001 (1-O-hexadecyloxypropyl-cidofovir) inhibits polyomavirus JC replication in human brain progenitor-derived astrocytes. Antimicrob Agents Chemother 55: 2129–2136.
46. Hall C. Dafni U. Simpson D. Clifford D. Wetherill P. Cohen B. et al. (1998) Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team. N Engl J Med 338:1345–1351.
47. Heilbronn R. Albrecht I. Stephan S. Burkle A. Zur Hausen H. (1993) Human cytomegalovirus induces JC virus DNA replication in human fibroblasts. Proc Natl Acad Sci USA 90: 11406–11410.
48. Hou J. Major E. (1998) The efficacy of nucleoside analogs against JC virus multiplication in a persistently infected human fetal brain cell line. J Neurovirol 4: 451–456.
49. Huang S. Skolasky R. Dal Pan G. Royal W. III McArthur J. (1998) Survival prolongation in HIV-associated progressive multifocal leukoencephalopathy treated with alpha-Interferon: An observational study. J Neuro Virol 4: 324–332.
50. Jelcic I. Martin R. Schippling S. Sospreda M. Yousef S. (2013) Polyoma virus JC peptides and proteins in vaccination and diagnostic applications. Patent WO 2013014134 A2.
51. Jiang Z.G. Cohen J. Marshall L.J. Major E.O. (2010) Hexadecyloxypropyl-cidofovir (CMX001) suppresses JC virus replication in human fetal brain SVG cell cultures. Antimicrob Agents Chemother 54: 4723–4732.
52. Josephson M. Javaid B. Kadambi P. Meehan S. Williams J. (2006) Leflunomide in solid organ transplantation and polyoma virus infection. In Ed. Ahsan N. (ed.), Polyomaviruses and Human Diseases. New York: Springer-Verlag.
53. Kappos L. (2011) Natalizumab-associated PML survival rates exceed 80%. ECTRIMS / ACTRIMS 5th joint triennial congress. Neurol Rev 10 (19): E4.
54. Kast R. Focosi D. Petrini M. Altschuler E. (2007) Treatment schedules for 5-HT2A blocking in progressive multifocal leukoencephalopathy using risperidone or ziprasidone. Bone Marrow Transplant 39: 811–812.
55. Katona S. (2009) JCV vaccination could reduce the risk of developing cognitive decline, dementia, strokes and brain tumours, by preventing chronic JCV cerebral infection, and recurrent reactivation. Med Hypotheses 73: 268–269.
56. Kerr D. Chang C. Gordon J. Bjornsti M. Khalili K. (1993) Inhibition of human neurotropic virus (JCV) DNA replication in glial cells by campto thecin. Virology 196: 612–618.
57. Khanna N. Elzi L. Mueller N. Garzoni C. Cavassini M. Fux C. et al. (2009) Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV cohort study. Clin Infect Dis 48: 1459–1466.
58. Kharfan-Dabaja M. Ayala E. Greene J. Rojiani A. Murtagh F. Anasetti C. (2007) Two cases of progressive multifocal leukoencephalopathy after allogeneic hematopoietic cell transplantation and a review of the literature. Bone Marrow Transplant 39: 253–254
59. Kitamura T. Kunitake T. Guo J. Tominaga T. Kawabe K. Yogo Y. (1994) Transmission of the human polyomavirus JC virus occurs both within the family and outside the family. J Clin Microbiol 32: 2359.
60. Kitamura T. Sugimoto C. Kato A. Ebihara H. Suzuki M. Taguchi F. et al. (1997) Persistent JC virus (JCV) infection is demonstrated by continuous shedding of the same JCV strains. J Clin Microbiol 35: 1255–1257.
61. Knowles W. (2006) Discovery and epidemiology of the human polyomaviruses BK virus (BKV) and JC virus (JCV). Adv Exp Med Biol 577: 19–45.
62. Koralnik I. (2006) Progressive multifocal leukoencephalopathy revisited: Has the disease outgrown its name? Ann Neurol 60: 162–173.
63. Kunitake T. Kitamura T. Guo J. Taguchi F. Kawabe K. Yogo Y. (1995) Parent-to-child transmission is relatively common in the spread of the human polyomavirus JC virus. J Clin Microbiol 33: 1448.
64. Kunschner L. Scott T. (2005) Sustained recovery of progressive multifocal leukoencephalopathy after treatment with IL-2. Neurology 65: 1510.
65. Lagatie O. van Loy T. Tritsmans L. Stuyver L. (2014) Viral miRNAs in plasma and urine divulge JC polyomavirus infection. Virol J 11: 158.
66. Maginnis M. Nelson C. Atwood W. (2014) JC polyomavirus attachment, entry, and trafficking: unlocking the keys to a fatal infection. J Neuro Virol. Epub ahead of print 31 July 2014. DOI: 10.1007/s13365-014-0272-4.
67. Marra C. Rajicic N. Barker D. Cohen B. Clifford D. Donovan Post M. et al. (2002) A pilot study of cidofovir for progressive multifocal leukoencephalopathy in AIDS. AIDS 16: 1791–1797.
68. Martin R. Sospedra M. Jelcic I. Yousef S. Schippling S. (2011) Polyoma virus JC peptides and proteins in vaccination and diagnostic applications. Patent EP 2548567 A1.
69. Matoba T. Orba Y. Suzuki T. Makino Y. Shichinohe H. Kuroda S. et al. (2008) An siRNA against JC virus (JCV) agnoprotein inhibits JCV infection in JCV-producing cells inoculated in nude mice. Neuropathology 28: 286–294.
70. Matos A. Duque V. Beato S. da Silva J. Major E. Meliço-Silvestr A. (2010) Characterization of JC human polyomavirus infection in a Portuguese population. J Med Virol 82: 494–504.
71. Mackall C. Fry T. Gress R. (2011) Harnessing the biology of IL-7 for therapeutic application. Nat Rev Immunol 11: 330–342.
72. Miller C. Houff S. Hopper J. Danaher R. Gurwell J. Lin Y. et al. (2012) No effect of disease modifying drugs on JC virus expression in multiple sclerosis. J Neurovirol 18: 411–415.
73. Molloy E. Calabrese L. (2009) Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases. Arthritis Rheum 60: 3761–3765.
74. Mommeja-Marin H. Marty F. Boeckh M. Winston D. Rowley S. Godkin S. et al. (2012) CMX001, a novel broad spectrum antiviral, may mitigate signs of BK virus (BKV) associated bladder and kidney end-organ damage. Poster at ICTS, July 2012
75. Moreno S. Miralles P. Díaz M. Berenguer J. de Quirós J. Blázquez R. et al. (1996) Cytarabine therapy for progressive multifocal leukoencephalopathy in patient with AIDS. Clin Infect Dis 23: 1066–1068.
76. Neff R. Hurst F. Falta E. Bohen E. Lentine K. Dharnidharka V. et al. (2008) Progressive multifocal leukoencephalopathy and use of mycophenolate mofetil after kidney transplantation. Transplantation 86: 1474–1478.
77. Nelson C. Carney D. Derdowski A. Lipovsky A. Gee G. O'Hara B. et al. (2013) A retrograde trafficking inhibitor of ricin and Shiga-like toxins inhibits infection of cells by human and monkey polyomaviruses. mBio 4: e00729.
78. Nelson C. Derdowski A. Maginnis M. O'Hara B. Atwood W. (2012) The VP 1 subunit of JC polyomavirus recapitulates early events in viral trafficking and is a novel tool to study polyomavirus entry. Virology 428: 30–40.
79. Newman J. Frisque R. (1997) Detection of archetype and rearranged variants of JC virus in multiple tissues from a pediatric PML patient. J Med Virol 52: 243–252.
80. Newman M. (2014) Orphan Drug Designation Granted to Treatment for Rare Multiple Sclerosis Drug Complication. Multiple Sclerosis News Today. Available at: http://multiplesclerosisnewstoday.com/2014/05/22/orphan-drug-designation-granted-treatment-rare-multiple-sclerosis-drug-complication/ (accessed August 2015)
81. Nukuzuma S. Kameoka M. Sugiura S. Nakamichi K. Nukuzuma C. Takegami T. (2013) Suppressive effect of PARP-1 inhibitor on JC virus replication in vitro. J Med Virol 85: 132–137.
82. O'Neill F. Greenlee J. Dörries K. Clawson S. Carney H. (2003) Propagation of archetype and nonarchetype JC virus variants in human fetal brain cultures: demonstration of interference activity by archetype JC virus. J Neurovirol 9: 567–576.
83. Orba Y. Sawa H. Iwata H. Tanaka S. Nagashima K. (2004) Inhibition of virus production in JC virus-infected cells by postinfection RNA interference. J Virol 78: 7270–7273.
84. Padgett B. Walker D. ZuRhein G. Eckroade R. Dessel B. (1971) Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet 1 (7712): 1257–1260.
85. Park J. Ryoo S. Noh H. Seo J. Kang H. Shin J. et al. (2011) Dual therapy with cidofovir and mirtazapine for progressive multifocal leukoencephalopathy in a sarcoidosis patient. Case Rep Neurol 3: 258–262.
86. Patel A. Patel J. Ikwuagwu J. (2010) A case of progressive multifocal leukoencephalopathy and idiopathic CD4+ lymphocytopenia. J Antimicrob Chemother 65: 2697–2698.
87. Phan-Ba R. Lommers E. Tshibanda L. Calay P. Dubois B. Moonen G. et al. (2012) MRI preclinical detection and asymptomatic course of a progressive multifocal leucoencephalopathy (PML) under natalizumab therapy. J Neurol Neurosurg Psychiatry 83: 224–226.
88. Pho M. Ashok A. Atwood W. (2000) JC virus enters human glial cells by clathrin-dependent receptor-mediated endocytosis. J Virol 74: 2288–2292.
89. Przepiorka D. Jaeckle K. Birdwell R. Fuller G. Kumar A. Huh Y. et al. (1997) Successful treatment of progressive multifocal leukoencephalopathy with low-dose interleukin-2. Bone Marrow Transplant 20: 983–987.
90. Querbes W. O'Hara B. Williams G. Atwood W. (2006) Invasion of host cells by JC virus identifies a novel role for caveolae in endosomal sorting of noncaveolar ligands. J Virol 80: 9402–9413.
91. Re D. Bamborschke S. Feiden W. Schröder R. Lehrke R. Diehl V. Tesch H. et al. (1999) Progressive multifocal leukoencephalopathy after autologous bone marrow transplantation and alpha-interferon immunotherapy. Bone Marrow Transplant 23: 295–298.
92. Reshef R. Luger S. Hexner E. Loren A. Frey N. Nasta S. et al. (2012) Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease. N Engl J Med 367: 135–145.
93. Riddell L. Pinching A. Hill S. Ng T. Arbe E. Lapham G. et al. (2001) A phase III study of recombinant human interferon gamma to prevent opportunistic infections in advanced HIV disease. AIDS Res Hum Retroviruses 17: 789–797.
94. Royal W. III Dupont B. McGuire D. Chang L. Goodkin K. Ernst T. et al. (2003) Topotecan in the treatment of acquired immunodeficiency syndrome-related progressive multifocal leukoencephalopathy. J Neurovirol 9: 411–419.
95. Sacktor N. Lyles R. Skolasky R. Kleeberger C. Selnes O. Miller E. et al. (2001) HIV-associated neurologic disease incidence changes: Multicenter AIDS Cohort Study, 1990–1998. Neurology 56: 257–260.
96. Schwab N. Höhn K. Schneider-Hohendorf T. Metz I. Stenner M. Jilek S. et al. (2012) Immunological and clinical consequences of treating a patient with natalizumab. Mult Scler 18: 335–44.
97. Sospedra M. Schippling S. Yousef S. Jelcic I. Bofill-Mas S. Planas R. et al. (2014) Treating progressive multifocal leukoencephalopathy with interleukin 7 and vaccination with JC Virus capsid protein VP1. Clin Infect Dis 59: 1588–1592.
98. Tan C. Ellis L. Wüthrich C. Ngo L. Broge T. Jr Saint-Aubyn J. et al. (2010) JC virus latency in the brain and extraneural organs of patients with and without progressive multifocal leukoencephalopathy. J Virol 84: 9200–9209.
99. Tan C. Koralnik I. (2010) Disorders caused by JC virus. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 9: 425–437.
100. Tan I. McArthur J. Clifford D. Major E. Nath A. (2011) Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology 77: 1061–1067.
101. Tan K. Roda R. Ostrow L. McArthur J. Nath A. (2009) PML-IRIS in patients with HIV infection: Clinical manifestations and treatment with steroids. Neurology 72: 1458–1464.
102. Taoufik Y. Gasnault J. Karaterki A. Ferey M. Marchadier E. Goujard C. et al. (1998) Prognostic value of JC virus load in cerebrospinal fluid of patients with progressive multifocal leukoencephalopathy. J Infect Dis 178: 1816–1820.
103. Tominaga T. Yogo Y. Kitamura T. Aso Y. (1992) Persistence of archetypal JC virus DNA in normal renal tissue derived from tumor-bearing patients. Virology 186: 736–741.
104. Verma S. Cikurel K. Koralnik I. Morgello S. Cunningham-Rundles C. Weinstein Z. et al. (2007) Mirtazapine in progressive multifocal leukoencephalopathy associated with polycythemia vera. J Infect Dis 196: 709–711.
105. von Geldern G. Pardo C. Calabresi P. (2012) Newsome SD. PML-IRIS in a patient treated with brentuximab. Neurology 79: 2075–2077.
106. Williams J. Javaid B. Kadambi P. Gillen D. Harland R. Thistlewaite J. et al. (2005) Leflunomide for polyomavirus type BK nephropathy N Engl J Med 352: 1157–1158.